Lepu Biopharma's MRG003 Trial Results Selected for American Society of Clinical Oncology Presentation

MT Newswires Live
03/28

Lepu Biopharma (HKG:2157) said results from its Phase IIb study of MRG003, an antibody drug conjugate for treating recurrent or metastatic nasopharyngeal cancer, were selected as a late-breaking abstract for oral presentation at the 2025 American Society of Clinical Oncology Annual Meeting, according to a Thursday filing on the Hong Kong Exchange.

MRG003 targets epidermal growth factor receptor (EGFR), which is highly expressed in various cancers, including colorectal, lung, and head and neck cancers, and 89% of advanced nasopharyngeal cancer cases.

The drug combines an EGFR-targeted monoclonal antibody with a microtubulin inhibitor payload, designed to kill tumor cells after internalization.

Lepu cautioned there is no assurance that MRG003 will be successfully developed and marketed.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10